Bristol Licenses Dragonfly’s IL-12 Program To Boost Immunotherapies

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The new collaboration announced 17 August is worth up to $475m in near-term upfront payments plus undisclosed milestone fees and royalties up to 24%.

Imagination idea and transition concept as a leaf changing to a butterfly shape as a fantasy travel and amazing inspirational spirit symbol in a 3D illustration style.
This is the first license of a program from Dragonfly's cytokine pipeline • Source: Shutterstock

Dragonfly Therapeutics, Inc. has signed many deals based on its TriNKET technology platform, but a new collaboration with long-time partner Bristol-Myers Squibb Company represents the first asset out-licensed from its cytokine pipeline, developed as complementary molecules to its NK-cell engagers. Bristol received a global exclusive license to Dragonfly’s interleukin 12 (IL-12) cytokine program, including lead candidate DF6002, which moved into its first clinical trial in July.

Bristol will pay Dragonfly undisclosed development, regulatory and commercial milestone fees plus royalties of up to 24% on worldwide net...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.